REMEGEN 09995Hong Kong Stock Exchange

70.4000.21%( +0.150 )
Closed: Oct 9 · Delayed · Hong Kong Stock Exchange
REMEGEN (09995) Company Profile - Company Info, Industry & Management - cibo

Company Information

Market
HKEX Main Board
Listing Date
2020-11-09
Industry
Innovative Drugs & Biologics
Fiscal Year End
Dec 31
ISIN
CNE1000048G6
Southbound Connect
Shanghai · Shenzhen

Related Securities

Industry

Innovative Drugs & Biologics 0.02%
124 stocks in this industry
Down 52 Up 57
Industry RankingsValue (HKD)Rank
Revenue (Last FY)3.80B29/112
Net Profit (Last FY)832.18M23/125
ROE (Last FY)19.66%10/117

Change is the 2026-10-09 close against the previous close; the industry change is the equal-weighted average of its stocks. Sub-industry classification is maintained by cibo. Last FY is each company's latest annual report. Net profit is profit attributable to owners of the parent; ROE = net profit / closing equity attributable to owners. Non-HKD statements are converted at ECB reference rates.

Management

NamePosition
RemeGen Co., Ltd. Executive Director
王威东 Executive Director
房健民 Executive Director
温庆凯 Executive Director
房艺 Executive Director
王玉晓 Executive Director
王荔强 Non-Executive Director
宋希亮 Independent Non-Executive Director
黄国滨 Independent Non-Executive Director
陈云金 Independent Non-Executive Director

Board list from the HKEXnews "List of Directors and their Role and Function", as of 2026-08-24.

About this page

This page shows REMEGEN (09995) company information, related securities, the price change distribution and in-industry rankings within its sub-industry, and the board of directors. Quotes come from HKEX Daily Quotations, financial metrics from each company's latest annual report, and the director list from HKEXnews.